<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=An_Selling_Point_Of_Sunitinib</id>
		<title>An Selling Point Of Sunitinib - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=An_Selling_Point_Of_Sunitinib"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=An_Selling_Point_Of_Sunitinib&amp;action=history"/>
		<updated>2026-05-12T07:29:24Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=An_Selling_Point_Of_Sunitinib&amp;diff=188725&amp;oldid=prev</id>
		<title>Yarn43angle: Створена сторінка: The rats from groups that received SAL or the lower-dose combination of ALD+ATV (0.01?mg/kg +?0.3?mg/kg, respectively) in prophylactic and therapeutic regimens...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=An_Selling_Point_Of_Sunitinib&amp;diff=188725&amp;oldid=prev"/>
				<updated>2017-06-13T13:10:20Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: The rats from groups that received SAL or the lower-dose combination of ALD+ATV (0.01?mg/kg +?0.3?mg/kg, respectively) in prophylactic and therapeutic regimens...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;The rats from groups that received SAL or the lower-dose combination of ALD+ATV (0.01?mg/kg +?0.3?mg/kg, respectively) in prophylactic and therapeutic regimens had their body mass measured before periodontitis induction and daily thereafter until day 11 [http://www.selleckchem.com/products/Sunitinib-Malate-(Sutent).html selleck products] after ligature placement. The data are presented as mean �� standard error of the mean or as median (range), where appropriate. ANOVA followed by the Bonferroni test or the Student's t-test were used to compare the means, and Kruskal�CWallis and Dunn tests were used to compare the medians. A p?value of [https://en.wikipedia.org/wiki/Fossariinae Fossariinae] with the lowest doses of ALD and ATV did not prevent alveolar bone loss (ALS 0.01?mg/kg?=?4.23?��?0.44?mm2 alveolar bone loss; ATV 0.3 mg/kg?= 4.16?��?0.35 mm2 alveolar bone loss) when compared with SAL (Fig.?1A); however, prophylactic monotherapy using the highest doses of ALD and ATV significantly prevented alveolar bone loss (ALD 0.25?mg/kg? = 2.1?��?0.1?mm2 alveolar bone loss; ATV 27?mg/kg? =?1.7?��?0.2?mm2 alveolar bone loss) when compared with SAL (SAL=4.6?��?0.2?mm2 alveolar bone loss) (p?[http://www.selleckchem.com/screening/pi3k-signaling-inhibitor-library.html Selleckchem PI3K Inhibitor Library] ALD+ATV was administered therapeutically, significant protection of alveolar bone (2.5?��?0.6?mm2 alveolar bone loss) (Fig.?2J) was also observed compared with administration of SAL or low-dose monotherapy with either ALD or ATV (Fig.?1C). The histometric study corroborated the morphometric and histological findings. It was observed that 11?d of ligature-induced alveolar bone loss caused intense alveolar bone loss when compared with the unchallenged periodontium. The lower-dose combination of ALD+ATV (0.01 mg/kg?+ 0.3?mg/kg, respectively), administered prophylactically or therapeutically, prevented and reduced alveolar bone loss compared with the administration of SAL (p?&lt;/div&gt;</summary>
		<author><name>Yarn43angle</name></author>	</entry>

	</feed>